GATOR1 GENE VARIANTS IN FOCAL EPIELPSY
Abstract
Significant genetic contributions to focal epilepsy have only recently been recognized, despite the well-established hereditary nature of other epilepsy syndromes. In 2013 the significant role of DEPDC5 gene in a rare familial focal epilepsy syndrome was described, followed by the discovery of variants in NPRL2 and NPRL3 genes in patients with similar clinical features three years later. The genes listed above code the three subunits that comprise the GTPase-activating protein (GAP) activity towards Rags 1 (GATOR1) complex, a negative regulator of mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). Loss of function of GATOR1 leads to constitutive mTORC1 activation that is linked to various malformations of cortical development (MCD), most notoriously focal cortical dysplasia (FCD), but has also been linked to epilepsy in the absence of overt MCD. Variants in GATOR1 genes have been detected in multiplex families with rare familial focal epilepsy syndromes where they demonstrate an autosomal dominant inheritance pattern with reduced penetrance. More recently, they have also been defined as major contributors in common nonacquired focal epilepsy in which they are detected in 3% of familial and 0.2% of sporadic cases and are particularly common in familial epilepsy associated with FCD where up to 11% of affected subjects carry gene variants. Clinical features of carriers include a propensity for nocturnal seizures, a poor response to antiseizure medication as well as an increased risk of sudden unexpected death in epilepsy, which is why other forms of treatment have been explored, including epilepsy surgery after which GATOR1 gene variant carriers have similar outcomes to other patients with focal epilepsy. A particularly promising avenue of exploration is the utilization of mTOR inhibitors like everolimus in epilepsy treatment, but further investigation into this option is warranted.
References
1. Lennox WG. The heredity of epilepsy as told by relatives and twins. J Am Med Assoc. 1951 Jun 9;146(6):529–36.
2. Nguyen DK, Mbacfou MT, Nguyen DB, Lassonde M. Prevalence of nonlesional focal epilepsy in an adult epilepsy clinic. Can J Neurol Sci J Can Sci Neurol. 2013 Mar;40(2):198–202.
3. Dibbens LM, de Vries B, Donatello S, Heron SE, Hodgson BL, Chintawar S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet. 2013 May;45(5):546–51.
4. Ishida S, Picard F, Rudolf G, Noé E, Achaz G, Thomas P, et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet. 2013 May;45(5):552–5.
5. Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013 May 31;340(6136):1100–6.
6. Ricos MG, Hodgson BL, Pippucci T, Saidin A, Ong YS, Heron SE, et al. Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol. 2016 Jan;79(1):120–31.
7. Baulac S. mTOR signaling pathway genes in focal epilepsies. Prog Brain Res. 2016;226:61–79.
8. Lasarge CL, Danzer SC. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front Mol Neurosci. 2014;7:18.
9. Moloney PB, Cavalleri GL, Delanty N. Epilepsy in the mTORopathies: opportunities for precision medicine. Brain Commun. 2021;3(4):fcab222.
10. Ribierre T, Baulac S. mTOR pathway in familial focal epilepsies. Oncotarget. 2016 Dec 26;8(4):5674–5.
11. Baldassari S, Ribierre T, Marsan E, Adle-Biassette H, Ferrand-Sorbets S, Bulteau C, et al. Dissecting the genetic basis of focal cortical dysplasia: a large cohort study. Acta Neuropathol (Berl). 2019 Dec;138(6):885–900.
12. Canavati C, Klein KM, Afawi Z, Pendziwiat M, Abu Rayyan A, Kamal L, et al. Inclusion of hemimegalencephaly into the phenotypic spectrum of NPRL3 pathogenic variants in familial focal epilepsy with variable foci. Epilepsia. 2019 Jun;60(6):e67–73.
13. Scheffer IE, Heron SE, Regan BM, Mandelstam S, Crompton DE, Hodgson BL, et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol. 2014 May;75(5):782–7.
14. Knudson AG. Mutation and Cancer: Statistical Study of Retinoblastoma. Proc Natl Acad Sci U S A. 1971 Apr;68(4):820–3.
15. Sim NS, Ko A, Kim WK, Kim SH, Kim JS, Shim KW, et al. Precise detection of low-level somatic mutation in resected epilepsy brain tissue. Acta Neuropathol (Berl). 2019 Dec;138(6):901–12.
16. Lee WS, Stephenson SEM, Pope K, Gillies G, Maixner W, Macdonald-Laurs E, et al. Genetic characterization identifies bottom-of-sulcus dysplasia as an mTORopathy. Neurology. 2020 Nov 3;95(18):e2542–51.
17. Lee WS, Stephenson SEM, Howell KB, Pope K, Gillies G, Wray A, et al. Second-hit DEPDC5 mutation is limited to dysmorphic neurons in cortical dysplasia type IIA. Ann Clin Transl Neurol. 2019;6(7):1338–44.
18. Samanta D. DEPDC5-related epilepsy: A comprehensive review. Epilepsy Behav EB. 2022 Apr 13;130:108678.
19. Epi4K consortium, Epilepsy Phenome/Genome Project. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol. 2017 Feb;16(2):135–43.
20. Epi25 Collaborative. Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. Am J Hum Genet. 2019 Aug 1;105(2):267–82.
21. Weckhuysen S, Marsan E, Lambrecq V, Marchal C, Morin-Brureau M, An-Gourfinkel I, et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia. 2016;57(6):994–1003.
22. Baldassari S, Picard F, Verbeek NE, van Kempen M, Brilstra EH, Lesca G, et al. The landscape of epilepsy-related GATOR1 variants. Genet Med Off J Am Coll Med Genet. 2019 Feb;21(2):398–408.
23. Klein KM, O’Brien TJ, Praveen K, Heron SE, Mulley JC, Foote S, et al. Familial focal epilepsy with variable foci mapped to chromosome 22q12: expansion of the phenotypic spectrum. Epilepsia. 2012 Aug;53(8):e151-155.
24. Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1443–74.
25. Stevelink R, Sanders MW, Tuinman MP, Brilstra EH, Koeleman BP, Jansen FE, et al. Epilepsy surgery for patients with genetic refractory epilepsy: a systematic review. Epileptic Disord Int Epilepsy J Videotape. 2018 Apr 1;20(2):99–115.
26. Scheffer IE, Bhatia KP, Lopes-Cendes I, Fish DR, Marsden CD, Andermann E, et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain J Neurol. 1995 Feb;118 ( Pt 1):61–73.
27. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 1995 Oct;11(2):201–3.
28. Picard F, Makrythanasis P, Navarro V, Ishida S, de Bellescize J, Ville D, et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology. 2014 Jun 10;82(23):2101–6.
29. Licchetta L, Pippucci T, Baldassari S, Minardi R, Provini F, Mostacci B, et al. Sleep-related hypermotor epilepsy (SHE): Contribution of known genes in 103 patients. Seizure. 2020 Jan;74:60–4.
30. Berkovic SF, Serratosa JM, Phillips HA, Xiong L, Andermann E, Díaz-Otero F, et al. Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12. Epilepsia. 2004 Sep;45(9):1054–60.
31. Rosanoff MJ, Ottman R. Penetrance of LGI1 mutations in autosomal dominant partial epilepsy with auditory features. Neurology. 2008 Aug 19;71(8):567–71.
32. Dazzo E, Fanciulli M, Serioli E, Minervini G, Pulitano P, Binelli S, et al. Heterozygous reelin mutations cause autosomal-dominant lateral temporal epilepsy. Am J Hum Genet. 2015 Jun 4;96(6):992–1000.
33. Michelucci R, Pasini E, Malacrida S, Striano P, Bonaventura CD, Pulitano P, et al. Low penetrance of autosomal dominant lateral temporal epilepsy in Italian families without LGI1 mutations. Epilepsia. 2013 Jul;54(7):1288–97.
34. Michelucci R, Poza JJ, Sofia V, de Feo MR, Binelli S, Bisulli F, et al. Autosomal dominant lateral temporal epilepsy: clinical spectrum, new epitempin mutations, and genetic heterogeneity in seven European families. Epilepsia. 2003 Oct;44(10):1289–97.
35. Bisulli F, Rinaldi C, Pippucci T, Minardi R, Baldassari S, Zenesini C, et al. Epilepsy with auditory features: Contribution of known genes in 112 patients. Seizure - Eur J Epilepsy. 2021 Feb 1;85:115–8.
36. Pippucci T, Licchetta L, Baldassari S, Palombo F, Menghi V, D’Aurizio R, et al. Epilepsy with auditory features: A heterogeneous clinico-molecular disease. Neurol Genet. 2015 Jun;1(1):e5.
37. Perucca P, Crompton DE, Bellows ST, McIntosh AM, Kalincik T, Newton MR, et al. Familial mesial temporal lobe epilepsy and the borderland of déjà vu. Ann Neurol. 2017 Aug;82(2):166–76.
38. Crompton DE, Scheffer IE, Taylor I, Cook MJ, McKelvie PA, Vears DF, et al. Familial mesial temporal lobe epilepsy: a benign epilepsy syndrome showing complex inheritance. Brain J Neurol. 2010 Nov;133(11):3221–31.
39. Striano P, Serioli E, Santulli L, Manna I, Labate A, Dazzo E, et al. DEPDC5 mutations are not a frequent cause of familial temporal lobe epilepsy. Epilepsia. 2015;56(10):e168–71.
40. Pippucci T, Licchetta L, Baldassari S, Marconi C, De Luise M, Myers C, et al. Contribution of ultrarare variants in mTOR pathway genes to sporadic focal epilepsies. Ann Clin Transl Neurol. 2019;6(3):475–85.
41. de Saint Martin A, Napuri S, Nguyen S. Tuberous sclerosis complex and epilepsy in infancy: prevention and early diagnosis. Arch Pediatr Organe Off Soc Francaise Pediatr. 2022 Dec;29(5S):5S8–13.
42. Carvill GL, Crompton DE, Regan BM, McMahon JM, Saykally J, Zemel M, et al. Epileptic spasms are a feature of DEPDC5 mTORopathy. Neurol Genet [Internet]. 2015 Aug 1 [cited 2022 Nov 19];1(2). Available from: https://ng.neurology.org/content/1/2/e17
43. Nascimento FA, Borlot F, Cossette P, Minassian BA, Andrade DM. Two definite cases of sudden unexpected death in epilepsy in a family with a DEPDC5 mutation. Neurol Genet. 2015 Dec;1(4):e28.
44. Wolking S, Moreau C, McCormack M, Krause R, Krenn M, EpiPGx Consortium, et al. Assessing the role of rare genetic variants in drug-resistant, non-lesional focal epilepsy. Ann Clin Transl Neurol. 2021 Jul;8(7):1376–87.
45. Baulac S, Ishida S, Marsan E, Miquel C, Biraben A, Nguyen DK, et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol. 2015 Apr;77(4):675–83.
46. Najm I, Lal D, Alonso Vanegas M, Cendes F, Lopes-Cendes I, Palmini A, et al. The ILAE consensus classification of focal cortical dysplasia: An update proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia. 2022 Aug;63(8):1899–919.
47. French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. The Lancet. 2016 Oct 29;388(10056):2153–63.
48. Parker WE, Orlova KA, Parker WH, Birnbaum JF, Krymskaya VP, Goncharov DA, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med. 2013 Apr 24;5(182):182ra53.
49. Myers KA, Scheffer IE. DEPDC5 as a potential therapeutic target for epilepsy. Expert Opin Ther Targets. 2017 Jun 3;21(6):591–600.
50. Kato M, Kada A, Shiraishi H, Tohyama J, Nakagawa E, Takahashi Y, et al. Sirolimus for epileptic seizures associated with focal cortical dysplasia type II. Ann Clin Transl Neurol. 2022;9(2):181–92.